Novo Nordisk A/S (Novo Nordisk A/S) Days Sales Outstanding

: 80.51 (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S's average Accounts Receivable for the three months ended in Dec. 2023 was $8,502 Mil. Novo Nordisk A/S's Revenue for the three months ended in Dec. 2023 was $9,636 Mil. Hence, Novo Nordisk A/S's Days Sales Outstanding for the three months ended in Dec. 2023 was 80.51.

The historical rank and industry rank for Novo Nordisk A/S's Days Sales Outstanding or its related term are showing as below:

NVO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 48.24 Med: 70.72 Max: 94.06
Current: 87.92

During the past 13 years, Novo Nordisk A/S's highest Days Sales Outstanding was 94.06. The lowest was 48.24. And the median was 70.72.

NVO's Days Sales Outstanding is ranked worse than
59.41% of 887 companies
in the Biotechnology industry
Industry Median: 72.66 vs NVO: 87.92

Novo Nordisk A/S's Days Sales Outstanding declined from Dec. 2022 (88.35) to Dec. 2023 (80.51).

Novo Nordisk A/S Days Sales Outstanding Historical Data

The historical data trend for Novo Nordisk A/S's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

72.20

72.45

91.36

96.88

89.56

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																88.35	85.97	93.45	89.28	80.51

Competitive Comparison

For the Biotechnology subindustry, Novo Nordisk A/S's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk A/S Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Novo Nordisk A/S's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Novo Nordisk A/S's Days Sales Outstanding falls into.

Novo Nordisk A/S Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Novo Nordisk A/S's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (7199.305	+	9476.503)	/	2 )	/	33982.121	*	365
=	8337.904					/	33982.121	*	365
=	89.56

Novo Nordisk A/S's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (7527.799	+	9476.503)	/	2 )	/	9636.42	*	365 / 4
=	8502.151					/	9636.42	*	365 / 4
=	80.51

Novo Nordisk A/S (NYSE:NVO) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Novo Nordisk A/S Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.